TRK xDFG Mutations Trigger a Sensitivity Switch from Type I to II Kinase Inhibitors.
Cancer Discovery
Cocco, Emiliano E; Lee, Ji Eun JE; Kannan, Srinivasaraghavan S; Schram, Alison M AM; Won, Helen H HH; Shifman, Sophie S; Kulick, Amanda A; Baldino, Laura L; Toska, Eneda E; Arruabarrena-Aristorena, Amaia A; Kittane, Srushti S; Wu, Fan F; Cai, Yanyan Y; Arena, Sabrina S; Mussolin, Benedetta B; Kannan, Ram R; Vasan, Neil N; Gorelick, Alexander N AN; Berger, Michael F MF; Novoplansky, Ofra O; Jagadeeshan, Sankar S; Liao, Yi Y; Rix, Uwe U; Misale, Sandra S; Taylor, Barry S BS; Bardelli, Alberto A; Hechtman, Jaclyn F JF; Hyman, David M DM; Elkabets, Moshe M; de Stanchina, Elisa E; Verma, Chandra S CS; Ventura, Andrea A; Drilon, Alexander A; Scaltriti, Maurizio M
Phase and context shape the function of composite oncogenic mutations.
Nature
Gorelick, Alexander N AN; Sánchez-Rivera, Francisco J FJ; Cai, Yanyan Y; Bielski, Craig M CM; Biederstedt, Evan E; Jonsson, Philip P; Richards, Allison L AL; Vasan, Neil N; Penson, Alexander V AV; Friedman, Noah D ND; Ho, Yu-Jui YJ; Baslan, Timour T; Bandlamudi, Chaitanya C; Scaltriti, Maurizio M; Schultz, Nikolaus N; Lowe, Scott W SW; Reznik, Ed E; Taylor, Barry S BS